Table 3.
Chaperone | Cancer type | Dysfunction | Proposed mechanism in promoting cancer | References | Variant |
---|---|---|---|---|---|
SRCAP | Ovarian cancer | Overexpression | N.D. | [89] | H2A.Z |
Metastatic breast carcinoma | Overexpression | N.D. | [84] | ||
Thyroid carcinoma | Overexpression | N.D. | [85] | ||
Prostate cancer | Overexpression | N.D. | [86] | ||
Prostate cancer | N.D. | Deregulation of cell proliferation | [20] | ||
Tip60 | Colon carcinomas | Downregulation | N.D. | [88] | |
Lung carcinomas | Downregulation | N.D. | [88] | ||
Breast carcinoma | Downregulation | N.D. | [87] | ||
p400 | Breast cancer | Overexpression | Activation of ERα target genes | [17] | |
HJURP | Lung cancer | Overexpression | Aneuploidy | [227] | CENP-A |
Breast cancer | Overexpression | Aneuploidy | [228] | ||
HIRA | Endothelial cells | Upregulation | Promotion of tumor neovascularization | [264] | H3.3 |
Daxx | GBM | Mutation | N.D. | [15] | |
PanNET | Mutation | Loss of function | [18, 19] | ||
ATRX | ATMDS | Mutation | Deregulation of α-globin expression | [266] | H3.3 (mH2A?) |
GBM | Mutation | Loss of nuclear localization | [15] | ||
Pediatric DIPG | Mutation | Loss of function | [16] | ||
Other cancers of the CNS | Mutation | Loss of nuclear localization | [279] | ||
Neuroblastoma | Mutation/deletion | Loss of function | [274] | ||
PanNET | Mutation/deletion | Loss of function | [18, 19] |